Stemcell Technologies plans on a global scale
This week, Conversations That Matter features the remarkable Dr. Allen Eaves, the founder, CEO and president of Stemcell Technologies, Canada’s most successful biotech company.
The firm is playing a pivotal role in fostering a community of biotech startups.
“We’re very keen to support an ecosystem of biotechnology here and be closely related with the universities, especially UBC and SFU, and, you know, this is my passion,” Eaves said.
Stemcell Technologies has experienced annual growth of 20 per cent over the past quarter-century and Eaves predicts that will continue.
“Over the next 15 years, we’re going to be hiring 5,000 more people and our sales will be well over $1 billion, and we’ll be even more of a global company. At only three per cent of our sales, the Canadian market is small,” he said.
Not only is Stemcell Technologies fostering growth and employing scientists, it is also playing a significant role in generating export sales, which Eaves said “are worth two to three times the value of dollars generated within an economy. And so we’re gonna continue to do this, and of course I would like to see this evolve into supporting all the things we do in health care.”
Where does he go from here? For Eaves, there are no limits. Not only does he plan to work for the rest of his life, he plans to do so with gusto.
“We are going for world domination,” he said, “and it’s all working out nicely.” Simon Fraser University’s Centre for Dialogue presents Conversations That Matter. Join veteran broadcaster Stuart McNish each week for an important and engaging conversation about the issues shaping our future.
Please become a subscriber and support the production of this program at conversationsthatmatter.tv.